Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of PANoptosis-related hub genes in acute myocardial infarction: diagnostic potential, immune correlates, and therapeutic insights.

Journal of cardiothoracic surgery·2026
Same author

Lycopene-mediated mitigation of cadmium-induced nephrotoxicity in broilers is associated with restoring mitochondrial homeostasis.

Poultry science·2026
Same author

Forsythiaside A Alleviates LPS-Induced Mastitis by Inhibiting Ferroptosis and Oxidative Stress.

Animals : an open access journal from MDPI·2026
Same author

Effects of Halliwick-based aquatic exercise on social and motor skills of children with autism spectrum disorder: a pilot study.

Frontiers in psychology·2026
Same author

Sebaceous Nevus Harboring an HRAS p.Ala11_Gly12dup Variant.

The Journal of dermatology·2026
Same author

Preoperative Questionnaire Evaluation and Testing for Latex Allergy: A Retrospective Study From 2015 to 2021.

The Journal of dermatology·2026

Related Experiment Video

Updated: Jun 29, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.8K

Chemo-Senolytic Therapeutic Potential against Angiosarcoma.

Xuebing Wang1, Claire Yik-Lok Chung1, Ai Yoshioka2

  • 1Division of Genome Biology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

The Journal of Investigative Dermatology
|April 3, 2024
PubMed
Summary
This summary is machine-generated.

This study explores a new angiosarcoma treatment combining chemotherapy and senolytic agents. A low-dose cisplatin and ABT-263 combination effectively eliminates senescent cancer cells, potentially reducing chemotherapy side effects.

Keywords:
AngiosarcomaCellular senescenceChemotherapySenescence-associated secretory phenotypeSenolytic agents

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.6K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K

Related Experiment Videos

Last Updated: Jun 29, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.8K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.6K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Angiosarcoma is an aggressive cancer with poor prognosis.
  • Current chemotherapy with paclitaxel shows limited efficacy due to chemoresistance.
  • There is a need for novel therapeutic strategies for angiosarcoma.

Purpose of the Study:

  • To investigate a combination therapy for angiosarcoma using chemotherapeutic and senolytic agents.
  • To evaluate the efficacy of cisplatin and paclitaxel in inducing senescence in angiosarcoma cells.
  • To assess the senolytic agent ABT-263 in eliminating senescent angiosarcoma cells.

Main Methods:

  • Induction of senescence in angiosarcoma cells using cisplatin and paclitaxel.
  • Treatment of senescent cells with the senolytic agent ABT-263.
  • Analysis of gene expression, including senescence-associated secretory phenotype (SASP) and IFN-I pathways.
  • Dose-response assessment of cisplatin for angiosarcoma cell elimination.

Main Results:

  • Cisplatin and paclitaxel effectively induce senescence in angiosarcoma cells.
  • ABT-263 eliminates senescent angiosarcoma cells via apoptosis.
  • Senescent cells exhibit activated SASP genes, which are downregulated by ABT-263.
  • Lower doses of cisplatin combined with ABT-263 are sufficient for angiosarcoma cell elimination compared to high-dose cisplatin alone.

Conclusions:

  • Combining low-dose cisplatin with the senolytic agent ABT-263 presents a promising therapeutic strategy for angiosarcoma.
  • This combination approach may reduce the toxic side effects associated with conventional chemotherapy.
  • Targeting senescent cells offers a novel avenue for angiosarcoma treatment.